Please login to the form below

Not currently logged in
Email:
Password:

AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

Joins as company prepares to advance APF350 to treat side effects of chemotherapy

Jesse Hollingsworth has left Dendreon to join AP Pharma as VP of sales.

The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting.

“Over the past several months, AP Pharma has been focused on recruiting key additions to our management team, and Jesse's experience in oncology sales will provide insights into the sales progamme for ... APF350,” said Robert Rosen, AP Pharma's chief commercial officer.

This experience includes Hollingsworth's time as senior director of group purchasing organisation and trade strategy at Dendreon, which developed the prostate cancer vaccine Provenge.

Prior to this role, Hollingsworth was senior director of strategic business development and marketing at ION Solutions.

This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.

5th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics